Cannabidivarin: Difference between revisions

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of ''C. indica'' ( = ''C. sativa'' ssp. ''indica'' var. ''kafiristanica'') from northwest [[India]], and in [[hashish]] from [[Nepal]].<ref>{{cite journal |vauthors=Turner CE, Cheng PC, Lewis GS, Russell MH, Sharma GK |year=1979 |title=Constituents of ''Cannabis sativa'' XV: Botanical and chemical profile of Indian variants |journal=Planta Medica |volume=37 |issue=3 |pages=217–25 | doi = 10.1055/s-0028-1097331}}</ref><ref>{{cite journal |vauthors=Hillig KW, Mahlberg PG |title=A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae) |journal=American Journal of Botany |volume=91 |issue=6 |pages=966–75 |year=2004 |pmid=21653452 |doi=10.3732/ajb.91.6.966 |doi-access=free }}</ref><ref name="HilligMahlberg">{{cite journal | vauthors = Hillig KW, Mahlberg PG | title = A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae) | journal = American Journal of Botany | volume = 91 | issue = 6 | pages = 966–75966–975 | date = June 2004 | pmid = 21653452 | doi = 10.3732/ajb.91.6.966 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Merkus FW | title = Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish | journal = Nature | volume = 232 | issue = 5312 | pages = 579–80579–580 | date = August 1971 | pmid = 4937510 | doi = 10.1038/232579a0 | s2cid = 4219797 | bibcode = 1971Natur.232..579M | s2cid = 4219797 }}</ref>

CBDV has anticonvulsant effects.<ref>{{cite journal | vauthors = Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, Futamura T, Duncan M, Stott CG, Stephens GJ, Williams CM, Whalley BJ | display-authors = 6 | title = Cannabidivarin is anticonvulsant in mouse and rat | journal = British Journal of Pharmacology | volume = 167 | issue = 8 | pages =1629–42 1629–1642 |year date = December 2012 | pmid = 22970845 | pmc = 3525866 | doi = 10.1111/j.1476-5381.2012.02207.x }}</ref> It was identified for the first time in 1969 by Vollner et al.<ref>{{Citecite journal |last=Vollner|first=L.|last2=Bieniek|first2=D.|last3=Korte|first3=F.|date=1969-01-01|title=Haschisch XX11XIX.vauthors Mitteillung:= F.Vollner von SpulakL, U.Bieniek ClaussenD, H.-W. Fehlhaber undKorte F. Korte,| Tetrahedrontitle 24,= 5379[Hashish. (1968)XX.: Cannabidivarin, eina neuernew hashish constituent] Haschisch-Inhaltsstoff| journal = Tetrahedron Letters | volume = 10 | issue = 3 | pages = 145–147 | date = January 1969 | pmid = 5778489 | doi = 10.1016/S0040-4039(01)87494-3|pmid=5778489|issn=0040-4039 }}</ref>

Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: [[Cannabidiol#Isomerism]]). It is not scheduled by [[Convention on Psychotropic Substances]]. It is being actively developed by [[GW Pharmaceuticals]] (as GWP42006)<ref name="GWPharm18">{{cite web |url=https://www.gwpharm.com/about/news/gw-pharmaceuticals-announces-preliminary-results-phase-2a-study-its-pipeline-compound |title=GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006 |publisher=GW Pharmaceuticals |date=21 February 2018 |access-date=28 May 2019}}</ref> because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.<ref>{{cite journal | vauthors = Amada N, Yamasaki Y, Williams CM, Whalley BJ | title = Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression | journal = PeerJ | volume = 1 | pages = e214 | year = 2013 | pmid = 24282673 | pmc = 3840466 | doi = 10.7717/peerj.214 }}</ref> GW has begun a phase 2 trial for adult [[epilepsy]],<ref>{{cite press release |title=GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin (CBDV) in Epilepsy |publisher=GW Pharmaceuticals |date=May 6, 2015 |url=http://globenewswire.com/news-release/2015/05/06/732705/10132893/en/GW-Pharmaceuticals-Initiates-Phase-2-Clinical-Study-of-Cannabidivarin-CBDV-in-Epilepsy.html |access-date=November 10, 2015 }}</ref> and is to begin trials of this CBDV product in children in 2016 in [[Australia]].<ref>{{Cite web|url = http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=938568|title = GW Pharma Press release|archive-url = https://web.archive.org/web/20151121025630/http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=938568|archive-date = 2015-11-21|url-status = dead}}</ref><ref>{{Cite web|url =http://www.health.nsw.gov.au/cannabis/Documents/medicial-cannabis-practitioners.pdf|title =NSW advice to practitioners on Medical Cannabis trials|archive-url =https://web.archive.org/web/20151121020442/http://www.health.nsw.gov.au/cannabis/Documents/medicial-cannabis-practitioners.pdf#|archive-date =2015-11-21|url-status =dead}}</ref>

== See also ==